DE60200202D1 - Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung - Google Patents

Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung

Info

Publication number
DE60200202D1
DE60200202D1 DE60200202T DE60200202T DE60200202D1 DE 60200202 D1 DE60200202 D1 DE 60200202D1 DE 60200202 T DE60200202 T DE 60200202T DE 60200202 T DE60200202 T DE 60200202T DE 60200202 D1 DE60200202 D1 DE 60200202D1
Authority
DE
Germany
Prior art keywords
particles
quinolinone derivative
preparation
water
particle diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60200202T
Other languages
English (en)
Other versions
DE60200202T2 (de
Inventor
Ryuji Kubota
Hiroshi Araya
Kouki Obata
Nobuyuki Kimura
Hiroyuki Fukui
Hidetsugu Takagaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mariposa Health Ltd Bilgola Plateau New Sou Au
Original Assignee
Dainippon Ink and Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Ink and Chemicals Co Ltd filed Critical Dainippon Ink and Chemicals Co Ltd
Publication of DE60200202D1 publication Critical patent/DE60200202D1/de
Application granted granted Critical
Publication of DE60200202T2 publication Critical patent/DE60200202T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60200202T 2001-06-20 2002-06-17 Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung Expired - Lifetime DE60200202T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001187138 2001-06-20
JP2001187138 2001-06-20

Publications (2)

Publication Number Publication Date
DE60200202D1 true DE60200202D1 (de) 2004-03-11
DE60200202T2 DE60200202T2 (de) 2004-12-30

Family

ID=19026474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60200202T Expired - Lifetime DE60200202T2 (de) 2001-06-20 2002-06-17 Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung

Country Status (10)

Country Link
US (1) US7081256B2 (de)
EP (1) EP1270006B1 (de)
KR (1) KR100908418B1 (de)
CN (1) CN1214791C (de)
AT (1) ATE258794T1 (de)
AU (1) AU778764B2 (de)
CA (1) CA2390746C (de)
DE (1) DE60200202T2 (de)
ES (1) ES2211844T3 (de)
TW (1) TWI299994B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533919C (en) * 2003-07-30 2010-10-12 Dainippon Ink And Chemicals, Inc. Therapeutic agent for chronic obstructive pulmonary disease and method for treating chronic obstructive pulmonary disease using the same
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
EP2100608A4 (de) * 2006-12-07 2009-12-09 Daiichi Sankyo Co Ltd Verfahren zur herstellung einer festen zubereitung
JP5274261B2 (ja) * 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
TWI428151B (zh) * 2006-12-07 2014-03-01 Daiichi Sankyo Co Ltd 含有甘露醇或乳糖之固形製劑
WO2008069262A1 (ja) * 2006-12-07 2008-06-12 Daiichi Sankyo Company, Limited 安定性が改善されたフィルムコーティング製剤
HUE035990T2 (en) * 2007-03-29 2018-05-28 Daiichi Sankyo Co Ltd Pharmaceutical preparation
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
CN103347520A (zh) 2010-10-13 2013-10-09 波士顿大学管理委员会 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂
US9815845B2 (en) 2010-10-13 2017-11-14 Trustees Of Boston University Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
US9802948B2 (en) 2010-10-13 2017-10-31 Trustees Of Boston Univeristy Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
WO2013022059A1 (ja) 2011-08-10 2013-02-14 第一三共株式会社 ジアミン誘導体含有医薬組成物
CA3108088A1 (en) 2018-08-02 2020-02-06 Trustees Of Boston University Late sv40 factor (lsf) inhibitors
US11242353B2 (en) 2020-01-24 2022-02-08 Trustees Of Boston University Heterocyclic LSF inhibitors and their uses
US11458132B2 (en) 2020-09-01 2022-10-04 Trustees Of Boston University Quinolin-2(1H)-one inhibitors of Late SV40 Factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
US5064837A (en) 1989-11-13 1991-11-12 Schering Corporation 3-substituted-1-aryl-2(h)-quinolones and their pharmaceutical compositions
JP2943725B2 (ja) 1996-01-17 1999-08-30 大日本インキ化学工業株式会社 キノリノン誘導体及びそれを有効成分とする抗アレルギー剤
TW430656B (en) * 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
TW505634B (en) * 1998-01-19 2002-10-11 Dainippon Ink & Amp Chemicals Quinolinone glucoside, the process for preparing thereof and antiallergic
JP3901832B2 (ja) * 1998-03-13 2007-04-04 大日本インキ化学工業株式会社 キノリノン誘導体製剤、及びその製造法
JP2000154137A (ja) * 1998-09-18 2000-06-06 Takeda Chem Ind Ltd 徐放性経口製剤
JP3901882B2 (ja) 1999-09-03 2007-04-04 大日本インキ化学工業株式会社 新規キノリノン誘導体製剤及びその製造方法
EP1129712A4 (de) 1999-09-10 2002-11-05 Dainippon Ink & Chemicals Präparate von quinolinonderivaten und deren herstellungsverfahren

Also Published As

Publication number Publication date
EP1270006A3 (de) 2003-02-26
EP1270006A2 (de) 2003-01-02
TWI299994B (en) 2008-08-21
US20030130310A1 (en) 2003-07-10
CN1214791C (zh) 2005-08-17
ATE258794T1 (de) 2004-02-15
ES2211844T3 (es) 2004-07-16
EP1270006B1 (de) 2004-02-04
AU4883502A (en) 2003-01-02
CN1391896A (zh) 2003-01-22
AU778764B2 (en) 2004-12-23
CA2390746A1 (en) 2002-12-20
KR20020096891A (ko) 2002-12-31
US7081256B2 (en) 2006-07-25
DE60200202T2 (de) 2004-12-30
CA2390746C (en) 2008-02-05
KR100908418B1 (ko) 2009-07-21

Similar Documents

Publication Publication Date Title
DE60200202D1 (de) Ein Chinolonderivat enthaltendes Arzneimittel und Verfahren zu dessen Herstellung
AU606149B2 (en) Pharmaceutical formulations
DK0923934T3 (da) Modified release-matrixformulering af cefaclor og cephalexin
WO1999006032A2 (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion
ATE381927T1 (de) Oral anzuwendendes arzneimittel bestehend aus einer vielzahl von mikrokapseln für die verzögerte verabreichung von wirkstoffen
CA2476496A1 (en) Controlled release dosage forms
PH26317A (en) Modified release gemfibrozil composition
WO2005117843A3 (en) Sustained release preparations
CA2346988A1 (en) Pharmaceutical formulation comprising omeprazole
WO2001078725A3 (en) Modified release formulations containing a hypnotic agent
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
AU2003208713B2 (en) Oral solid solution formulation of a poorly water-soluble active substance
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
ATE386725T1 (de) Heterocyclylverbindungen
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2008099615A1 (ja) 微粒子油性懸濁液を含む医薬組成物
MXPA01012751A (es) Microgranulos de sulfato de morfina, procedimiento para su preparacion y composicion que los contiene.
GB2098867A (en) Sustained release pharmaceutical composition
CA2499273A1 (en) Inhalation compositions
AU3283100A (en) Controlled-release compositions of betahistine
ITMI951772A1 (it) Composizione coprente con un film e preparazioni solide che utilizzano la stessa
JPS6117510A (ja) 口腔粘膜適用徐放性ニフエジピン製剤
JP2007001873A (ja) コーティング組成物及びコーティングされた固形製剤
CA1209042A (en) Therapeutic granules
CA2520813A1 (en) Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ACTIVUS PHARMA CO.,LTD., YOTSUKAIDO, CHIBA, JP

8327 Change in the person/name/address of the patent owner

Owner name: MARIPOSA HEALTH LTD., BILGOLA PLATEAU, NEW SOU, AU